LFST vs CHE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LFST · LifeStance Health$13.82 ▲ 3.60%
CHE · Chemed$548.59 ▼ 0.50%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LFST +123.1%
- CHE +26.4%
Head to head
| Metric | LFST | CHE |
|---|---|---|
| Price | $13.82 | $548.59 |
| Change today | ▲ 3.60% | ▼ 0.50% |
| Market cap | $5.25B | $7.11B |
| Return, 3 months | +13.7% | +3.7% |
| Return, year to date | +96.3% | +28.7% |
| Return, 1 year | +114.6% | +27.4% |
| P/E (TTM) | 76.8 | 26.3 |
| P/B | 3.5 | 8.3 |
| P/E percentile vs own 5y | 86th | 31st |
| Dividend yield | – | 0.46% |
| Revenue growth (YoY, latest qtr) | +25.3% | +10.6% |
| Net profit growth (YoY) | +1,978.5% | +11.5% |
| Gross margin | 34.4% | 33.5% |
| Operating margin | 6.2% | 14.0% |
| Net margin | 4.3% | 10.6% |
| Return on equity | 4.8% | 29.1% |
| Analyst target vs. price | +24.0% | +11.6% |
| Analyst buy share | 89% | 60% |
| RSI (14) | 54 | 61 |
| 30-day volatility | 44.5% | 24.8% |
| Max drawdown, 1 year | -17.1% | -23.0% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CHE is the largest of the group by market value.
- LFST has returned the most over the past year.
- CHE carries the lowest trailing P/E.
- LFST is growing revenue fastest.
- CHE keeps the most profit per dollar of sales.
- CHE has been the calmest stock over the last 30 days.